% | $
Quotes you view appear here for quick access.

SIGA Technologies Inc. Message Board

  • ret6408 ret6408 Dec 7, 2013 9:30 AM Flag

    WHO advisory committee on variola virus. Report of 15th meeting

    Very good reading. Sounds like we're getting closer to FDA approval. Also not much interest in funding other antivirals with ST 246 and CMX001 nearly approved. No further need for primate testing for us although FDA wants intradermal rabbit pox model.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • OT for ret. Thanks for the CADX. An new suggestions?

      • 2 Replies to tweendalines
      • Major advances have been made in this field. Two compounds, tecovirimat (ST-246; Arestvyr) and brincidofovir (CMX001), which are active and have different mechanisms of action, are well advanced along the regulatory pathway to licensure for smallpox. Tecovirimat has been tested in many animal models and has demonstrated unequivocal protection against orthopoxviruses, including variola virus, in these models. The US FDA has requested additional limited studies with the intradermal rabbitpox model and the intranasal ectromelia model in mice but stated that, at present, more work with live variola virus is not needed for these compounds. Despite not being licensed, ST-246 has been purchased for the US Strategic National Stockpile. A series of other potential compounds are in much earlier stages of development as medical countermeasures against smallpox.

      • Think CREE is a good long term play on the LED lighting area.
        SNGX worth a look on the bioterrorism area.

0.90-0.0500(-5.26%)3:37 PMEDT